Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues

Expert Review of Anticancer Therapy

Volumn 11, Issue 6, 2011, Pages 853-858

  Lammers, Rianne J M ^a   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

bladder cancer; FISH; HER2; immunohistochemistry; prognosis; targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CYSTECTOMY; HUMAN; LYMPHADENECTOMY; ONCOGENE NEU; PATIENT SELECTION; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

EID: 79959790567     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.58     Document Type: Article

References (42)

1. Wu X, Ros MM, Gu J, Kiemeney L. Epidemiology and genetic susceptibility to bladder cancer. BJU Int. 102(9 Pt B), 1207-1215 (2008
2. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66(6 Suppl. 1), 4-34 (2005 (Pubitemid 43049607)
3. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49(3), 466-465 (2006
4. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54(2), 303-314 (2008
5. Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of non muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178(6), 2314-2330 (2007 (Pubitemid 350080987)
6. Gschwend JE, Dahm P, Fair WR. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur. Urol. 41(4), 440-448 (2002 (Pubitemid 35333942)
7. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001 (Pubitemid 32120143)
8. Stenzl A, Cowan NC, De SM et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. 55(4), 815-825 (2009
9. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229(4717), 974-976 (1985 (Pubitemid 16248488)
10. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151(6), 1523-1530 (1997 (Pubitemid 27527914)
11. Klapper LN, Glathe S, Vaisman N et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl Acad. Sci. USA 96(9), 4995-5000 (1999 (Pubitemid 29214524)
12. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 5(1), 63-69 (2004 (Pubitemid 38821193)
13. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007 (Pubitemid 350003059)
14. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res. 7(7), 1957-1962 (2001
15. Jimenez RE, Hussain M, Bianco FJ Jr et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. 7(8), 2440-2447 (2001 (Pubitemid 32751647)
16. Gandour-Edwards R, Lara PN Jr, Folkins AK et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95(5), 1009-1015 (2002 (Pubitemid 34925350)
17. Kruger S, Weitsch G, Buttner H et al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int. J. Oncol. 21(5), 981-987 (2002
18. Ramos SD, Navarro FS, Villamon FR, Gil SM, Llombart BA. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors]. Arch. Esp. Urol. 56(3), 277-285 (2003
19. Tsai YS, Tzai TS, Chow NH et al. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan. Urol. Int. 71(3), 262-270 (2003
20. Simon R, Atefy R, Wagner U et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int. J. Cancer 107(5), 764-772 (2003 (Pubitemid 37339730)
21. Kruger S, Lange I, Kausch I, Feller AC. Protein expression and gene copy number analysis of topoisomerase 2a, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder - a multitissue array study with prognostic implications. Anticancer Res. 25(1A), 263-271 (2005 (Pubitemid 40470119)
22. Chakravarti A, Winter K, Wu CL et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 62(2), 309-317 (2005 (Pubitemid 40704444)
23. Rajjayabun PH, Keegan PE, Lunec J, Mellon JK. erbB receptor expression patterns in human bladder cancer. Urology 66(1), 196-200 (2005 (Pubitemid 41002227)
24. Wulfing C, von SD, Bierer S, Bogemann M, Hertle L, Eltze E. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy]. Aktuelle Urol. 36(5), 423-429 (2005 (Pubitemid 41411615)
25. Tsai YS, Tzai TS, Chow NH. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Urol. Int. 79(3), 210-216 (2007
26. Kolla SB, Seth A, Singh MK et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int. Urol. Nephrol. 40(2), 321-327 (2008
27. Liedberg F, Anderson H, Chebil G et al. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol. Oncol. 26(1), 17-24 (2008
28. Skagias L, Politi E, Karameris A et al. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research. J. BUON. 14(3), 457-462 (2009
29. Naruse K, Yamada Y, Nakamura K et al. Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder. Oncol. Rep. 23(6), 1577-1583 (2010
30. Bolenz C, Shariat SF, Karakiewicz PI et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 106(8), 1216-1222 (2010
31. Caner V, Turk NS, Duzcan F et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol. Oncol. Res. 14(3), 261-266 (2008
32. Matsubara H, Yamada Y, Naruse K et al. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol. Rep. 19(1), 57-63 (2008 (Pubitemid 351176131)
33. Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br. J. Cancer 94(11), 1703-1709 (2006 (Pubitemid 43924936)
34. Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/ neu-positive urothelial carcinoma: results of a multicenter Phase II National Cancer Institute trial. J. Clin. Oncol. 25(16), 2218-2224 (2007 (Pubitemid 46954646)
35. Wulfing C, Machiels JP, Richel DJ et al. A single-arm, multicenter, open-label Phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115(13), 2881-2890 (2009
36. Pruthi RS, Nielsen M, Heathcote S et al. A Phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 106(3), 349-354 (2010
37. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068-3077 (2000
38. Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann. Oncol. 21(4), 815-819 (2010).
39. Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res. Treat. 34(2), 97-117 (1995
40. Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24(2), 85-95 (1992 (Pubitemid 23063891)
41. Colquhoun AJ, McHugh LA, Tulchinsky E, Kriajevska M, Mellon JK. Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo. J. Radiat. Res. (Tokyo) 48(5), 351-360 (2007 (Pubitemid 47451246)
42. Maddineni SB, Sangar VK, Hendry JH, Margison GP, Clarke NW. Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br. J. Cancer 92(1), 125-130 (2005). (Pubitemid 40188445)